Astellas enters into agreement to acquire Audentes Therapeutics
TOKYO: Astellas Pharma Inc. and Audentes Therapeutics Inc. have entered into a definitive agreement for Astellas to acquire Audentes at a price of US$60.00per share in cash, representing a total equity value of approximately US$3 billion. “Recent scientific and technological…